Background: Developmental disabilities have diverse genetic causes that must be identified to 38 facilitate precise diagnoses. We describe genomic data from 371 affected individuals, 309 of 39 which were sequenced as proband-parent trios. Methods: Whole exome sequences (WES) 40 were generated for 365 individuals (127 affected) and whole genome sequences (WGS) were 41 generated for 612 individuals (244 affected). Results: Pathogenic or likely pathogenic variants 42 were found in 100 individuals (27%), with variants of uncertain significance in an additional 42 43 (11.3%). We found that a family history of neurological disease, especially the presence of an 44 affected 1 st degree relative, reduces the pathogenic/likely pathogenic variant identification 45 rate, reflecting both the disease relevance and ease of interpretation of de novo variants. We 46 also found that improvements to genetic knowledge facilitated interpretation changes in many 47 cases. Through systematic reanalyses we have thus far reclassified 15 variants, with 11.3% of 48 families who initially were found to harbor a VUS, and 4.7% of families with a negative result, 49 eventually found to harbor a pathogenic or likely pathogenic variant. To further such progress, 50 the data described here are being shared through ClinVar, GeneMatcher, and dbGAP. 51 Conclusion: Our data strongly support the value of large-scale sequencing, especially WGS 52 within proband-parent trios, as both an effective first-choice diagnostic tool and means to 53 advance clinical and research progress related to pediatric neurological disease. 54 55 KEYWORDS 56 Developmental Delay, Intellectual Disability, De novo, clinical sequencing, CSER 57 58 3 BACKGROUND 59 Developmental delay, intellectual disability, and related phenotypes (DD/ID) affect 1-2% of 60 children and pose medical, financial, and psychological challenges [1]. While many are genetic 61 in origin, a large fraction of cases are not diagnosed, with many families undergoing a 62 "diagnostic odyssey" involving numerous ineffective tests over many years. A lack of diagnoses 63 undermines counseling and medical management and slows research towards improving 64 educational or therapeutic options. 65 66 Standard clinical genetic testing for DD/ID includes karyotype, microarray, Fragile X, single 67 gene, gene panel, and/or mitochondrial DNA testing [2]. The first two tests examine an 68 individual's entire genome with low resolution, while the latter offer higher resolution but over 69 a small fraction of a person's genome. Whole exome or genome sequencing (WES or WGS) can 70 provide both broad and high-resolution identification of genetic variants, and hold great 71 promise as effective diagnostic assays [3]. 72 73 As part of the Clinical Sequencing Exploratory Research (CSER) consortium [4], we have 74 sequenced 371 individuals with one or more DD/ID-related phenotypes. 100 affected 75 individuals (27%) were found to harbor a pathogenic or likely pathogenic (P/LP) variant, most of 76 which were de novo. 16% of P/LP variants were identified upon re-analysis that took place after 77 initial assessment and results return, supporting the value of systematic reanalysis of variant 78 data to maximize clinical effectiveness. We also describe 21 variants of uncertain significance 79 (VUS) in 19 genes not currently associated with disease but which are intriguing candidates. The 80 4 genomic data we generated and shared through dbGAP [5], ClinVar [6], and GeneMatcher [7] 81 may prove useful to other clinical genetics labs and researchers. Our experiences and data 82 strongly support the value of large-scale sequencing for clinical and research progress related to 83 pediatric neurological disease. 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 5 METHODS 103 IRB approval and monitoring 104 Review boards at Western (20130675) and the University of Alabama at Birmingham 105 (X130201001) approved and monitored this study. 106 107 Study participant population 108 Participants were enrolled at North Alabama Children's Specialists in Huntsville, AL. A parent or 109 legal guardian was required to give consent for all probands, and assent was obtained from 110 those probands who were capable. Probands were required to be at least two years of age, 111 weigh at least 9 kilos (19.8 lbs), and be affected with developmental and/or intellectual delays; 112 more detailed information regarding enrollment, including phenotypic criteria, is provided in 113 the Supplemental Methods.
For reanalysis, variants were reannotated with additional data, including updated versions of 149 ClinVar [6] , ExAC [15] , DDG2P [16] , and gene or variant lists identified in publications related to 150 DD/ID genetics [17] [18] [19] , and refiltered as described above and in Supplemental Methods. 151 Candidate variants found in genes that were either not known to associate with disease or were 152 found in individuals with phenotypes dissimilar from previously reported associations were 153 submitted to GeneMatcher (https://genematcher.org/) [7] .
155
Variant classification 156 Variants were classified into one of five categories: pathogenic, likely pathogenic, VUS, likely Variant validation 169 WES and WGS were carried out under a research protocol and were not completed within a 170 CAP/CLIA laboratory. All variants found to be medically relevant and returnable were validated 171 by Sanger sequencing in an independent CLIA laboratory (Emory Genetics Laboratory) before 172 being returned to participants, although these validated variant results are not CLIA-compliant 173 as the input DNA was originally isolated in a research laboratory. 176 For probands subjected to WGS as part of trios, we removed parental genotype information 177 from their associated VCFs and subsequently filtered to identify variants that are expected to 178 be extremely rare in the general population and/or affect genes known to associate with 179 disease (Figure 2 , Table S3 ). Scores from the Combined Annotation Dependent Depletion 180 (CADD) algorithm [21] were subsequently used to rank P/LP variants within the filtered variant 191 Demographics of study population 192 We enrolled 339 families (977 individuals total) with at least one proband with an unexplained 193 diagnosis of a DD/ID-related phenotype (see "Study participant population" in Supplemental 194 Methods). 284 participating families were enrolled with both biological parents. 261 of these 195 families had one affected proband, while 21 families had two affected probands, and an 196 additional two families had three affected probands. As each proband (including siblings within 197 a family) was used to anchor a proband-parent "trio" as an analytical unit, our study includes a 198 total of 309 trios from 284 families. We also enrolled 35 proband-parent "duos" that included 199 one proband and one biological parent. Additionally, we enrolled two families with one 200 biological parent and two affected probands (4 "duos"), and one duo family with three affected 201 probands (3 "duos"), leading to a total of 42 "duos" from 38 families. Finally, we enrolled 17 202 "singleton" families in which no parents were available for testing; for 14 of these only one 203 proband was tested, and in three families, two affected siblings were sequenced (total of 20 204 "singleton" probands). 205 206 During the course of this study, a decision to replace WES with WGS was made. In total, WES 207 was performed on 365 individuals (127 affected) and WGS was performed on 612 individuals 208 (244 affected). WES and WGS were sequenced to an average depth of 71X and 35X, 209 respectively, with >80% of bases covered ≥ 20X in both experiment types. DNA from probands 210 subjected to WES was also analyzed via a SNP array to detect copy-number variants (CNV) if 211 clinical array testing had not been previously performed.
Analysis of trios as singletons

RESULTS
The study population had a mean age of 11 years and was 58% male. Affected individuals 213 displayed symptoms described by 333 unique HPO [22] terms with over 90% of individuals 214 displaying intellectual disability, 69% with speech delay, 45% with seizures, and 20% with 215 microcephaly or macrocephaly. 18% of affected individuals had an abnormal brain magnetic 216 resonance imaging (MRI) result and 81% of individuals had been subjected to genetic testing 217 prior to enrollment in this study (Table 1) . and other sources of evidence; these assertion criteria are described in detail in the 226 Supplemental Methods. All variants described here were confirmed by Sanger sequencing (see 227 Methods) in probands and available family members before being returned to participants.
228 229 100 (27%) of the 371 probands had P/LP variants, while an additional 42 (11.3%) harbored a 230 VUS ( Table 2) . Given that most probands had been previously tested via microarray prior to 231 their enrollment in this study, large CNVs classified as a VUS or greater were detected in only 11 232 affected individuals (Table 2; Table S2 ; Figure S1 ).
233
Most (76%) P/LP variation occurred de novo, while 12% of individuals inherited P/LP variants as 235 compound heterozygotes or homozygotes ( Figure S2A ). An additional 5% were males with an X-236 linked maternally inherited P/LP variant. Finally, 7% of participants who harbored a P/LP result 237 were sequenced with one or no biological parent and thus have unknown inheritance ( Figure   238 S2A). Most P/LP variants were missense mutations (52%), while 39% were nonsense or 239 frameshift, 7% were predicted to disrupt splicing, and 2% led to inframe deletion ( Figure S2B ).
240
Variants that were classified as a VUS or greater were identified in 97 genes, excluding large 241 CNVs, with variants in 23 (24%) of these genes observed in two or more unrelated individuals 242 (Tables S1 and S2). Affected individuals were categorized into one of three analytical structures based on the 247 number of parents that were sequenced along with the proband(s): proband-parent trios (309); 248 duos with one parent (42); and proband-only singletons (20). A P/LP result was found in 29.1% 249 of trio individuals, 19% of duo individuals, and 15% of singletons (Table 1) .
251
We believe that at least some of the decline in P/LP variant yield in duos and singletons reflects 252 the analytical benefits of trio sequencing to efficiently highlight de novo variation. However,
253
given that one or both biological parents were unavailable or unwilling to participate in duo or 254 singleton analyses, the P/LP rate comparisons among trios/duos/singletons may be confounded 255 by other disease-associated factors (depression, schizophrenia, ADHD, etc.). For example, most (11 of 20) of the singleton probands were adopted owing to death or disability associated with 257 neurological disease in their biological parents. To assess the relationship between 258 identification of a P/LP variant and family history, we separated all probands into three types: 259 simplex families in which there was only one affected proband and no 1 st to 3 rd degree relatives 260 reported to be affected with any neurological condition (n=93); families in which the enrolled 261 proband had no affected 1 st degree relatives but with one or more reported 2 nd or 3 rd degree 262 relatives who were affected with a neurological condition (n=85); and multiplex families in 263 which the proband had at least one first degree relative affected with a neurological condition 264 (n=123) ( Table S4 ). Thirty-eight probands with limited or no family history information were 265 excluded from this analysis. identification rate that is twice as high for simplex, relative to multiplex, families. While larger 270 sample sizes are needed to confirm this effect, the rate difference is significant whether or not 271 all enrolled families (p=0.002) or only those sequenced as trios (p=0.008) are considered. Rates 272 in families that were neither simplex nor multiplex (i.e., proband lacks an affected 1 st degree 273 relative but has one or more affected 2 nd or 3 rd degree relatives) were intermediate, with 26% 274 of all such families having a P/LP result (28% of trios). Of relevance to the trio/duo/singleton 275 comparison described above, 11 of 13 (85%) singletons for which we had family history 276 information had an affected 1 st degree relative, in contrast with 41% for duos and 39% for trios 277 (Table S4 ). This enrichment for affected 1 st degree relatives likely contributed to the generally 278 reduced rate of P/LP variants in singletons observed here.
280
Multiplex family findings include examples of both expected and unexpected inheritance 281 patterns. For example, two affected male siblings were found to be hemizygous for a nonsense 282 mutation in PHF6 (Börjeson-Forssman-Lehmann syndrome MIM:301900) inherited from their 283 unaffected mother. In another family, we found the proband to be compound heterozygous for 284 two variants in GRIK4, with one allele inherited from each parent. Interestingly, both the 285 mother and father of this proband report psychiatric illness, and extended family history of 286 psychiatric phenotypes is notable. While these data are insufficient to conclude that they are 287 indeed causative, it is plausible that the observed psychiatric phenotypes are at least partially 288 attributable to the variation in GRIK4 found in this family. We also observed independent de 289 novo causal variants within two families. Affected siblings in family 00135 each harbored a 290 returnable de novo variant in a different gene, including a VUS in SPR (Dystonia MIM:612716) 291 and a pathogenic variant in RIT1 (Noonan syndrome MIM:615355), while two probands (00075-292 C and 00078-C) who were second degree relatives to one another harbored independent 293 pathogenic de novo variants, one each in DDX3X (X-linked ID MIM:300958) and TCF20 (Table   294   S2 ).
296
Alternative mechanisms of disease 297 While the majority of DD/ID-associated genetic variation found here is predicted to lead to 298 predicted to disrupt splicing, and in some cases, potentially alternative mechanisms of disease.
300
As an example, we sequenced an affected 14-year-old girl (00003-C, Table S2) 
307
It is likely that both the canonical and cryptic splice sites function, allowing for most MECP2 308 transcripts to produce full-length protein, resulting in the milder Rett phenotype observed in 309 the individual described here and the girl described by Laccone and colleagues [23] .
311
In another affected proband (00126-C), we identified compound heterozygous variants in ALG1 312 (Table S2 ). This proband has phenotypes consistent with ALG1-CDG (congenital disorder of 313 glycosylation MIM:608540) including severe ID, hypotonia, growth retardation, microcephaly, 314 and seizures, and was included as part of a comprehensive study of ALG1-associated 315 phenotypes [24] . The paternally inherited missense mutation (c.773C>T (p.S258L)) has been 316 previously reported as pathogenic [25] , while the maternally inherited variant, which has not 317 been observed before (c.1187+3A>G), is three bases downstream of an exon/intron junction 318 ( Figure 1A ). We performed qPCR from patient blood RNA and found that intron 11 of ALG1 is 319 completely retained in both the proband and the mother ( Figure 1A -D). The retention of intron 320 In a separate family consisting of affected maternal half siblings (00218-C and 00218-S, Table   322 S2, Figure 1E ) we found a variant in a canonical splice acceptor site (c.505-2A>G) of MTOR 323 intron 4. The half siblings described here both have ID; the younger sibling has no seizures but 324 has facial dysmorphism, speech delay, and autism, while his older sister exhibits seizures. We 325 presume that the maternal half siblings inherited the splice variant from their mother, for 326 whom DNA was not available, who was reported to exhibit seizures. We conducted qPCR and 327 Sanger sequencing using blood-derived RNA from both siblings, finding transcripts that included 328 an additional 134 nucleotides from the 3' end of intron 4, ultimately leading to the addition of 329 20 amino acids before a stop-gain ( Figure 1F -H, Figure S3 ). Because the stop-gain occurs early in phenotypes observed in this family and previously reported families, we find this variant to be 336 highly intriguing and suggestive that MTOR loss-of-function variation may also lead to disease.
337
MTOR is highly intolerant of mutations in the general population (RVIS [28] score of 0.09%) 338 supporting the hypothesis that loss-of-function is deleterious and likely leads to disease 339 consequences. 
Proband-only versus trio sequencing 344
Our trio-based study design allows rapid identification of de novo variants, which are enriched 345 among variants that are causally related to deleterious, pediatric phenotypes [29] . However, we 346 also assessed to what extent our P/LP rate would differ if we had only enrolled probands. Thus, 347 and to avoid the confounding of family history differences among trios, duos, and singletons 348 (see above), we subjected variants found by WGS within all trio-based probands to various 349 filtering scenarios blinded to parental status and assessed the CADD score [21] ranks of de novo 350 variants previously classified as P/LP ( Figure 2 ; Table S3 ). While parentally informed filters were 351 the most sensitive and efficient (e.g., >60% of P/LP variants were the top-ranked variant among 352 the list of all de novo events in each respective proband), filters defined without parental 353 information were also effective. For example, among all rare, protein-altering (i.e., missense, (Table S3 ).
362
In contrast to P/LP variants, VUSs would have been more difficult to identify without parental 363 sequencing ( Figure S4 ), owing to the fact that many VUSs do not affect genes known to 364 associate with disease. Also, those VUSs that do affect genes known to associate with disease tended to have lesser computationally estimated effects, and therefore lower CADD ranks [21] ; 366 if they were more overtly deleterious, they would likely have been classified as P/LP. Discovery 367 of candidate or novel disease associations, many of which are likely to eventually be shown as 368 robust, is thus substantially more effective within trios.
370
Secondary findings in participating parents 371 We found genetic variation unrelated to DD/ID, i.e., secondary findings, in 8.7% of parents 372 (Table S5 ). One and a half percent of parents were found to harbor a P/LP variant related to a 373 self-reported secondary condition, such as variants in SLC22A5 that underlie a primary carnitine 374 deficiency (MIM:212140). We also examined 56 genes identified by the ACMG as potentially 375 harboring actionable secondary findings [14] , revealing P/LP variants in 12 parents (2.0%), a 376 rate similar to that observed in other cohorts [14, 30] . Finally, we performed a limited carrier 377 screening assessment, identifying 28 (4.6%) parents as carriers of P/LP variation in HBB (Sickle 
Reanalysis of WES and WGS data 384
To exploit steady increases in human genetic knowledge, we performed systematic reanalyses 385 of WES/WGS data. We approached reanalysis in three ways: 1) systematic reanalysis of old 386 data, with the goal of reassessing each dataset every 12 months after initial analysis; 2) mining of variant prompted by new DD/ID genetic publications; and 3) use of GeneMatcher [7] to aid in 388 the interpretation of variants in genes of uncertain disease significance.
390
As shown in Table 3 , these efforts led to an increase in pathogenicity score for 15 variants in 17 391 individuals. In nine cases, a new publication became available that allowed a variant that had 392 not been previously reported, or that was previously reported as a VUS, to be reclassified as Additionally, of the 211 families who originally received a negative result, P/LP variation was 402 identified for 10 (4.7%) through reanalysis. These data show that regular reanalysis of both 403 uncertain and negative results is an effective mechanism to improve diagnostic yield.
405
Identification of novel candidate genes 406 We have identified 21 variants within 19 genes with no known disease association but which 
418
While these variants remain VUSs, the fact that they are de novo, predicted to be deleterious, 419 and affect genes under strong selective conservation in human populations, suggests they have 420 a good chance to be disease-associated. We have sequenced 371 individuals with various DD/ID-related phenotypes. 27% percent of 424 these individuals harbored a P/LP variant, most of which were de novo and protein-altering. We 425 found that the P/LP yield is impacted by presence of neurological disease in family members, as 426 our success rate drops from 38% for probands without any affected relatives to 19.5% for 427 probands with one or more affected 1 st degree relatives. These data are consistent with the 428 observation of higher causal variant yields in simplex families relative to multiplex families 429 affected with autism [33] . It in part reflects the eased interpretation of de novo causal variation 430 relative to inherited, and likely in many cases variably expressive or incompletely penetrant, causal variation (e.g., 16p12) [34] . 432 433 127 probands were subject to WES and 244 were subject to WGS. The P/LP identification rate 434 was not significantly different between the two assays when considering only SNVs or small 435 indels (p=0.30). However, WGS is a better assay for detection of CNVs [35] and, while our 436 patient population is depleted for large causal CNVs owing to prior array or karyotype testing, 437 we have identified CNVs that we classified as P/LP in eight individuals.
439
We have also demonstrated the value of systematic reanalysis, which has thus far yielded P/LP 440 variants for an additional 17 individuals (17% of total P/LP variants, 4.6% of total probands).
441
Given the rates of progress in Mendelian disease genetics [36] and the development of new 442 genomic annotations, we believe that systematic reanalysis of genomic data should become 443 standard practice. While the costs and logistical demands for implementation at large scales are 444 unclear, re-analysis has the potential to considerably increase diagnostic yields over time (e.g., 445 in our study, ~8% for cases > 1 year removed from initial analysis). Furthermore, as more 446 pathogenic coding and non-coding variants are found, the reanalysis benefit potential is largest 447 for WGS relative to WES; the former typically has slightly better coverage of coding exons in 448 both our data (Table S6 ) and previous studies [35] , and re-analysis of pathogenic non-coding 449 variation is impossible with WES. Our data clearly suggests trio-based sequencing as more sensitive and analytically efficient than 452 proband-only sequencing, supporting the value of trios in clinical diagnostics; as sequencing costs continue to drop, testing parents should eventually be offered routinely. Further, VUSs 454 and novel candidates are more difficult to identify without parental sequence data, and 455 proband-only approaches will ultimately confer less benefit in terms of discovery of new 456 disease associations. However, current sequencing costs, when coupled to overall priorities 457 (e.g., per-patient yield vs. total number of diagnoses) may lead to variability in decision-making 458 about how to best allocate resources. For example, tripling per-patient sequencing costs will, 459 under many realistic cost scenarios, lead to fewer total diagnoses within a given total budget 460 even though the per-patient diagnostic yield is higher and curation time reduced for trios 461 relative to singletons. Our retrospective analyses, in which we evaluated ranks of pathogenic 462 variants under various filtering parameters, may provide useful information in making these 463 decisions. Trade-offs in curation time, which will correlate with P/LP variant ranks, and 464 sensitivity can be estimated empirically, in relative terms, using these data ( Figure 2 ; Table S3 ).
466
Variation detected through our studies has already helped lead to the discovery of at least one 467 new disease association, as we identified two patients that harbor de novo variants in EBF3, a 468 highly conserved transcription factor involved in neurodevelopment that is relatively intolerant 469 to mutations in the general population (RVIS [28]: 6.78%). Through collaboration with other 470 researchers via GeneMatcher [7], we were able to identify a total of 10 DD/ID-affected 471 individuals who harbor EBF3 variants, supporting that de novo disruption of EBF3 function leads 472 to neurodevelopmental phenotypes [37] . It is our hope that the other VUSs described here, to GAPDH. The sequences of all oligos used are found in Table S7 . under models that only consider population frequencies (e.g., "Rare"), rank (based on CADD) 689 among the top 25 hits in a patient, and many rank as the top hit. Restrictions to rare coding 690 variants and/or those affecting OMIM/DDG2P [13, 16] L  i  k  e  l  y  p  a  t  h  o  g  e  n  i  c  r  a  t  e  s  b  y  c  l  i  n  i  c  a  l  a  n  n  o  t  a  t  i  o  n  a  n  d  f  a  m  i  l  y  s  t  r  u  c  t  u  r  e  a  m  o  n  g  t  h  e  3  7  1  D  D  /  I  D  -a  f  f  e  c  t  e  d  i  n  d  i  v  i  d  u  a  l  s  C  H  A  R  A  C  T  E  R  I  S  T  I  C   %  I  n  d i 
